Talk:Indacaterol/glycopyrronium bromide

This is the talk page for discussing improvements to the Indacaterol/glycopyrronium bromide article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Indacaterol/glycopyrronium bromide.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.

Ed at Sunovion (talk · contribs) has been paid by Sunovion on their behalf.

Proposed changes

Part of an edit requested by an editor with a conflict of interest has been implemented.

Hello, I am a Sunovion employee and would like to help update this Wikipedia entry. There are updates that are needed that I would like to work with you on to ensure it’s updated according to Wikipedia guidelines. I look forward to working with you.

Please add ‘In 2016, Novartis licensed its U.S. commercial rights for Seebri Neohaler and Utibron Neohaler to Sunovion Pharmaceuticals.’

The source for this edit is https://www.drugdeliverybusiness.com/sunovion-novartis-ink-licensing-deal-inhaled-copd-drugs/

Also, add ‘In 2017, the FDA approved Lonhala Magnair, a new drug product, to be marketed by Sunovion Pharmaceuticals.’

The source for this edit is https://www.drugs.com/history/lonhala-magnair.html

Thanks for your help Ed at Sunovion (talk) 18:30, 13 December 2019 (UTC)[reply]

Reply 13-DEC-2019

Edit request partially implemented

Y The claim regarding the commercial rights was added to the article.
N The claim regarding Lonhala Magnair was not added to the article.

Regards, Spintendo 20:25, 13 December 2019 (UTC)[reply]

Proposed changes

This edit request by an editor with a conflict of interest was declined. Per: WP:NOTPROMO.

Hello, I am a Sunovion employee and would like to help update this Wikipedia page with this edit.

Add ‘In 2017, the FDA approved Lonhala Magnair (glycopyrrolate) Inhalation Solution for the treatment of COPD to be marketed by Sunovion Pharmaceuticals.’

The source for this edit is https://journals.sagepub.com/doi/full/10.1177/1060028018798753

Thanks for your help Ed at Sunovion (talk) 20:59, 13 December 2019 (UTC)[reply]